SCHEMBL1743230

SCHEMBL1743230

CC1CCN(C(=O)c2ccccc2B(O)O)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.61
KDM4E B2RXH2 2/20 0.58
RAB9A P51151 4/20 0.52
NPC1 O15118 3/20 0.52
GRM5 P41594 1/20 0.51
ALDH1A1 P00352 6/20 0.50
HPGD P15428 5/20 0.50
SMN1; SMN2 Q16637 4/20 0.50
ALOX15 P16050 1/20 0.50
HSD17B10 Q99714 1/20 0.50
TP53BP1 Q12888 1/20 0.50
L3MBTL3 Q96JM7 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
GAA P10253 1/20 0.49
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
TP53 P04637 1/20 0.48
MAPT P10636 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
LMNA P02545 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10723852 0.88 ACHE (0.71) ACHEKDM4ERAB9ANPC1GRM5
SCHEMBL29954605 0.86 HTT (0.58) RAB9AALDH1A1SMN1; SMN2L3MBTL1MEN1
SCHEMBL4443752 0.83 TSHR (0.62) ALDH1A1HPGDSMN1; SMN2HSD17B10TP53BP1
SCHEMBL29956909 0.83 HTT (0.64) ALDH1A1HPGDSMN1; SMN2TP53BP1L3MBTL3
SCHEMBL10274564 0.82 ALDH1A1 (0.70) ACHEKDM4EALDH1A1HPGDKMT2A
SCHEMBL13503962 0.81 KDM4E (0.84) ACHEKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL10535520 0.81 ACHE (0.61) ACHEKDM4ERAB9ANPC1GRM5
SCHEMBL10274559 0.81 RAB9A (0.72) ACHEKDM4ERAB9ANPC1ALDH1A1
SCHEMBL6411599 0.80 L3MBTL1 (0.69) KDM4ERAB9AGRM5ALDH1A1HPGD
SCHEMBL12859460 0.79 ACHE (0.59) ACHEKDM4ERAB9ANPC1GRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8846677-B2 Medicaments HIGH POINT PHARMACEUTICALS, LLC (US) 2014-09-30 US disclosed
US-8501739-B2 Medicaments HIGH POINT PHARMACEUTICALS, LLC (US) 2013-08-06 US disclosed
US-20120232078-A1 Novel Medicaments HIGH POINT PHARMACEUTICALS, LLC (US) 2012-09-13 US disclosed
EP-2386554-A1 Compounds active at the histamine H3 receptor High Point Pharmaceuticals, LLC (US) 2011-11-16 EP disclosed
EP-2233470-A1 Histamine H3 receptor antagonists High Point Pharmaceuticals, LLC (US) 2010-09-29 EP disclosed
US-20090312309-A1 Novel Medicaments HIGH POINT PHARMACEUTICALS, LLC (US) 2009-12-17 US disclosed
EP-1902028-A2 HISTAMINE H3 RECEPTOR ANTAGONISTS Novo Nordisk A/S (DK) 2008-03-26 EP disclosed
WO-2007003604-A2 HISTS1MINE H3 RECEPTOR ANTAGONISTS NOVO NORDISK A/S (DK) 2007-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232078-A1 Novel Medicaments HRH3, HRH4, HRH1 ACHE 695/4885KDM4E 3732/4885RAB9A 4607/4885
US-20090312309-A1 Novel Medicaments HRH3, HRH4, HRH1 ACHE 695/4885KDM4E 3732/4885RAB9A 4607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.